EFFECTS OF A POTENT PEROXYNITRITE DECOMPOSITION CATALYST IN MURINE MODELS OF ENDOTOXEMIA AND SEPSIS

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author SORIANO, Francisco Garcia FMUSP-HC
LORIGADOS, Clara Batista FMUSP-HC
PACHER, Pal
SZABO, Csaba
dc.date.issued 2011
dc.identifier.citation SHOCK, v.35, n.6, p.560-566, 2011
dc.identifier.issn 1073-2322
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/22648
dc.description.abstract Excessive free-radical production due to various bacterial components released during bacterial infection has been linked to cell death and tissue injury. Peroxynitrite is a highly reactive oxidant produced by the combination of nitric oxide (NO) and superoxide anion, which has been implicated in cell death and tissue injury in various forms of critical illness. Pharmacological decomposition of peroxynitrite may represent a potential therapeutic approach in diseases associated with the overproduction of NO and superoxide. In the present study, we tested the effect of a potent peroxynitrite decomposition catalyst in murine models of endotoxemia and sepsis. Mice were injected i.p. with LPS 40 mg/kg with or without FP15 [Fe(III) tetrakis-2-(N-triethylene glycol monomethyl ether) pyridyl porphyrin] (0.1, 0.3, 1, 3, or 10 mg/kg per hour). Mice were killed 12 h later, followed by the harvesting of samples from the lung, liver, and gut for malondialdehyde and myeloperoxidase measurements. In other subsets of animals, blood samples were obtained by cardiac puncture at 1.5, 4, and 8 h after LPS administration for cytokine (TNF-alpha, IL-1 beta, and IL-10), nitrite/nitrate, alanine aminotransferase, and blood urea nitrogen measurements. Endotoxemic animals showed an increase in survival from 25% to 80% at the FP15 doses of 0.3 and 1 mg/kg per hour. The same dose of FP15 had no effect on plasma levels of nitrite/nitrate. There was a reduction in liver and lung malondialdehyde in the endotoxemic animals pretreated with FP15, as well as in hepatic myeloperoxidase and biochemical markers of liver and kidney damage (alanine aminotransferase and blood urea nitrogen). In a bacterial model of sepsis induced by cecal ligation and puncture, FP15 treatment (0.3 mg/kg per day) significantly protected against mortality. The current data support the view that peroxynitrite is a critical factor mediating liver, gut, and lung injury in endotoxemia and septic shock: its pharmacological neutralization may be of therapeutic benefit.
dc.description.sponsorship · National Institutes of Health [R01GM060915]
· Shriners Burns Hospitals [8661]
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Shock
dc.rights restrictedAccess
dc.subject.other lecithinized superoxide-dismutase; ischemia-reperfusion injury; septic shock; nitric-oxide; vascular dysfunction; lipid-peroxidation; nitrosative stress; circulatory shock; dose-response; rabbit heart
dc.title EFFECTS OF A POTENT PEROXYNITRITE DECOMPOSITION CATALYST IN MURINE MODELS OF ENDOTOXEMIA AND SEPSIS
dc.type article
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.group LIM/51
dc.identifier.doi 10.1097/SHK.0b013e31820fe5d5
dc.identifier.pmid 21263378
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author SORIANO, Francisco Garcia:FM:MCM
hcfmusp.author LORIGADOS, Clara Batista:HC:IOT
hcfmusp.author.external · PACHER, Pal:NIAAA, Lab Physiol Studies, NIH, Bethesda, MD USA
· SZABO, Csaba:Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA
hcfmusp.origem.id WOS:000290662700004
hcfmusp.origem.id 2-s2.0-79957888168
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Marshall JC, 2010, SURG INFECT, V11, P275, DOI 10.1089/sur.2010.024
· Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222
· Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P73, DOI 10.1124/jpet.106.108100
· McCord JM, 2008, DOSE-RESPONSE, V6, P223, DOI 10.2203/dose-response.08-012.McCord
· Levrand S, 2005, J BIOL CHEM, V280, P34878, DOI 10.1074/jbc.M501977200
· Ulloa L, 2009, CURR PHARM DESIGN, V15, P1918, DOI 10.2174/138161209788453248
· Texereau J, 2004, CRIT CARE MED, V32, pS313, DOI 10.1097/01.CMM.0000126363.46191.DC
· Obrosova IG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1645, DOI 10.1152/ajpendo.00479.2007
· Freeman BD, 2000, EXPERT OPIN INV DRUG, V9, P1651, DOI 10.1517/13543784.9.7.1651
· Pacher P, 2008, AM J PATHOL, V173, P2, DOI 10.2353/ajpath.2008.080019
· Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313
· Ishihara T, 2009, J PHARMACOL EXP THER, V328, P152, DOI 10.1124/jpet.108.144451
· Tanaka KI, 2010, AM J PHYSIOL-LUNG C, V298, pL348, DOI 10.1152/ajplung.00289.2009
· Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604
· Cuzzocrea S, 2001, PHARMACOL REV, V53, P135
· Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x
· Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019
· Genovese T, 2009, FREE RADICAL RES, V43, P631, DOI 10.1080/10715760902954126
· Maybauer DM, 2008, BIOCHEM BIOPH RES CO, V377, P786, DOI 10.1016/j.bbrc.2008.10.066
· Vincent JL, 2002, CLIN INFECT DIS, V34, P1084, DOI 10.1086/339549
· Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
· Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
· Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD
· Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008
· Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718
· Loukili N, 2010, J BIOL CHEM, V285, P15746, DOI 10.1074/jbc.M110.103259
· Soriano FG, 2006, CRIT CARE MED, V34, P1073, DOI 10.1097/01.CCM.0000206470.47721.8D
· Bianchi C, 2002, ANN THORAC SURG, V74, P1201, DOI 10.1016/S0003-4975(02)03953-X
· GALINANES M, 1992, J MOL CELL CARDIOL, V24, P1021, DOI 10.1016/0022-2828(92)91868-6
· Lange M, 2010, CRIT CARE, V14, DOI 10.1186/cc9097
· LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71
· Mabley JG, 2002, MOL MED, V8, P581
· Maybauer DM, 2011, SHOCK, V35, P148, DOI 10.1097/SHK.0b013e3181eb4556
· Naidu BV, 2003, J HEART LUNG TRANSPL, V22, P784, DOI 10.1016/S1053-2498(02)00556-9
· NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0
· OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2
· Radovits T, 2007, MECH AGEING DEV, V128, P173, DOI 10.1016/j.mad.2006.09.005
· Szabo C, 2002, MOL MED, V8, P571
· SZABO C, 1995, FEBS LETT, V372, P229, DOI 10.1016/0014-5793(95)00984-H
· Szabo C, 2010, SHOCK, V34, P4, DOI 10.1097/SHK.0b013e3181e7e9ba
· Tauskela JS, 2006, NEUROSCI LETT, V401, P236, DOI 10.1016/j.neulet.2006.03.046
· WINTERS BD, 2010, CRIT CARE MED, V38, pY1283
· Wittebole X, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/568396
· ZACHAROWSKI K, 2000, CRIT CARE MED, V28, P953
dc.description.index MEDLINE
hcfmusp.citation.scopus 35
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Estados Unidos
hcfmusp.scopus.lastupdate 2021-07-14


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics